Articles related to IMMUNOTHERAPY

A phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in patients with unresectable stage III NSCLC and no progression after concurrent chemoradiotherapy. With a median follow-up of 11.5 months, both combinations increased ORR and prolonged PFS versus durvalumab alone. Safety was similar across arms with no new or significant safety signals identified with either combination.

Perelman School of Medicine’s David Teachey, MD, reviews outcomes and implications from two recent Children’s Oncology Group trials and describes current research with daratumumab and CAR T-cell therapy.

The authors analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4 Th cells that appear to be directly involved in the anti-tumor immune response.

Phase 1 trial using an autologous CAR-T cell therapy that targets the oncofetal antigen Claudin-6 (CLDN6) — and CARVac (BioNTech), a CLDN6-encoding mRNA-based vaccine designed to enhance CAR T-cell activity. Data show encouraging clinical activity for an investigational CAR T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

Neo-adjuvant therapy with nivolumab and ipilimumab is associated with a high pCR rate in ptsd with MSI/dMMR resectable OGA.

In this updated analysis of the KEYNOTE-177 study, although pembrolizumab continued to show durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups.